Maryland universities ranked first among the nation’s top graduate programs and schools in three out of 15 categories.
Image: State House (from Francis St.), Annapolis, Maryland, February 2014. Photo by Diane F. Evartt.
BERLIN (Reuters) – Genetic testing specialist Qiagen received emergency use authorization for a new coronavirus test from the U.S. drugs regulator FDA, it said on Monday.
“This polymerase chain reaction (PCR) multiplex test will be an important tool now and in upcoming winter seasons for simultaneous qualitative detection and differentiation of influenzas A and B, respiratory syncytial virus (RSV) and SARS-CoV-2 infections within 80 minutes,” the company said in a statement.
Identifying gaps and bridging them—that’s what Connected DMV’s President and CEO Stu Solomon does best. And now he and his partners are turning their attention to one of the globe’s most important and challenging divides: Preparing for the next pandemic.
Solomon recently discussed his career and Connected DMV’s response to COVID-19 with Rich Bendis on his BioTalk podcast. Bendis is the President and CEO of BioHealth Innovation (BHI).
MainStreet qualifies software, hardware, and venture-backed startups for 200+ unclaimed tax credits accountants don’t check for.
We do all the paperwork and you get cash. If we can’t help you claim any credits, you pay $0.
GSK has reached an agreement in principle with Novavax and the UK Government Vaccines Taskforce to support manufacturing of up to 60 million doses of Novavax’ COVID-19 vaccine candidate (NVX-CoV2373) for use in the UK. GSK will provide ‘fill and finish’ manufacturing capacity at its Barnard Castle facility in the North East of England beginning as early as May 2021, with a rapid technology transfer between the two companies beginning immediately. The parties will negotiate a final agreement to include additional terms and conditions.
As the supply of Covid-19 vaccines begins to widen toward meeting the immense demand, some observers have proposed that policy makers put college students close to the top of the list.
Christopher R. Marsicano, head of the College Crisis Initiative at Davidson College, argued in a recent op-ed that vaccinating college students would help protect everyone. “The broader principle in administering vaccine shots equitably is to diminish the risk for those who are most at danger to spread the virus,” he wrote. “Vaccinating college students is an effective way to lower that danger, for two major reasons: College students are mobile and spread Covid-19 with them whenever they travel, and they live in congregate living facilities where infection rates are much higher than in other housing setups.”
Image: https://www.chronicle.com/
The region has been at the forefront of the SARS-CoV-2 vaccine race, and it is rapidly becoming a center for advanced manufacturing. The BHCR cell and gene therapy ecosystem is thriving, and the area boasts one of the richest and most diverse tapestries of life science talent and workforce development programming. What’s more, Maryland, Washington, DC, and Virginia are home to several dynamic university systems that keep the talent and tech transfer pipeline humming and full.
Image: https://biobuzz.io
The National Institutes of Health provides significant funding for drug development research to universities, companies, and organizations. Over the course of 2020, the NIH provided a significant amount of funding to the BioHealth Capital Region.
The top recipients of NIH funding in the BHCR were research universities, with Johns Hopkins University topping the list with $807,432,003 in financing for different research programs. The top 10 recipients of NIH funding in the BioHealth Capital Region secured more than $2.18 billion in financing. Life sciences organizations within the state of Maryland secured $2.3 billion in NIH funding, an increase from the $1.9 billion granted in 2019.
“I’m delighted by GSK’s investment, which shows the strength of UK manufacturing, and will further boost our vaccine rollout. The Vaccines Taskforce has worked hand in glove with business to successfully deliver vaccines to the whole of the UK, and this agreement will continue to support our approach. We remain on track to offer a first jab to all over 50s by 15 April, and all adults by the end of July, and I want to once again encourage everyone to come forward for a vaccine when you’re called,” said Prime Minister Boris Johnson.
TCR² Therapeutics Inc., based in Cambridge, is a clinical-stage company that develops T-cell therapies for patients with cancer. In a statement, TCR² said it signed a long-term, full-building lease for an existing 85,000 sq. ft. facility. The company will build-out the space to be used for quality control laboratories and offices as well as clinical and commercial production of gavo-cel, the company’s lead product targeting solid tumors. According to a federal form, 15 years is the initial term for the lease at 9950 Medical Center Drive.